Department of Women's and Children's Health, Karolinska University Hospital and Institute, Stockholm, Sweden.
Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
J Cancer Educ. 2021 Feb;36(1):126-133. doi: 10.1007/s13187-019-01608-0.
This study aims to investigate acceptance of vaginal self-sampling for high-risk human papilloma virus (HPV) among long-term screening non-attenders at increased cervical cancer risk and to identify leverage points to promote screening adherence among these women. Forty-three long-term screening non-attenders performed home vaginal self-sampling for HPV, had positive HPV results, and subsequently attended gynecologic examination. Sixteen (37.2%) had high-grade cervical intraepithelial neoplasia (CIN2 or 3), and two had invasive cervical cancer. Forty-one of these women completed a questionnaire concerning Specific Knowledge about HPV, CIN, and cervical cancer, potential barriers to screening and views about self-sampling. Results were compared with 479 women treated for CIN2+ who attended gynecologic follow-up and also performed self-sampling. Significant multivariate predictors of long-term non-attender status compared with referents were low Specific Knowledge, high confidence in self-sampling, and potential barriers-refraining from activity to attend gynecologic examination, needing another's help to attend, and long travel time. Non-attenders citing fear/refraining from gynecologic examination as why they preferred self-sampling significantly more often had lowest Specific Knowledge compared with other non-attenders. All non-attenders could envision themselves doing self-sampling again while only 74% of referents endorsed this statement (p = 0.0003). We conclude that HPV self-sampling is an acceptable option for women at increased cervical cancer risk who have been long-term screening non-attenders. Educational outreach to enhance Specific Knowledge about HPV, CIN and cervical cancer is critical. Those non-attenders who explicitly avoid gynecologic examinations need special attention. Trial Registry: Clinicaltrials.gov NCT02750124.
本研究旨在调查在高宫颈癌风险下长期筛查不参与者中,对阴道自我采样进行高危型人乳头瘤病毒(HPV)检测的接受程度,并确定在这些女性中促进筛查依从性的杠杆点。43 名长期筛查不参与者在家中进行了 HPV 阴道自我采样,结果 HPV 阳性,随后接受了妇科检查。其中 16 人(37.2%)患有高级别宫颈上皮内瘤变(CIN2 或 3),2 人患有浸润性宫颈癌。这些女性中有 41 人完成了一份关于 HPV、CIN 和宫颈癌的特定知识、筛查潜在障碍以及对自我采样的看法的问卷。结果与 479 名接受 CIN2+治疗并接受妇科随访且也进行自我采样的女性进行了比较。与参照者相比,长期筛查不参与者的显著多变量预测因素是特定知识水平低、对自我采样的高度信心以及潜在的障碍——避免活动接受妇科检查、需要他人帮助才能接受检查和旅行时间长。因害怕/避免妇科检查而选择自我采样的不参与者与其他不参与者相比,特定知识水平显著较低。所有不参与者都能想象自己再次进行自我采样,而只有 74%的参照者表示赞同(p = 0.0003)。我们得出的结论是,HPV 自我采样对于长期筛查不参与者且有较高宫颈癌风险的女性来说是一个可接受的选择。进行有关 HPV、CIN 和宫颈癌的特定知识的教育推广至关重要。那些明确避免妇科检查的不参与者需要特别关注。试验注册:Clinicaltrials.gov NCT02750124。